Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262620 | PMC |
| http://dx.doi.org/10.1056/NEJMc2108861 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Randomized, Blinded, Vehicle-Controlled Dose-Ranging Study to Evaluate and Characterize Remdesivir Efficacy Against Ebola Virus in Rhesus Macaques.
Viruses
December 2024
Gilead Sciences, Inc., Foster City, CA 94404, USA.
Ebola virus (EBOV) causes severe disease in humans, with mortality as high as 90%. The small-molecule antiviral drug remdesivir (RDV) has demonstrated a survival benefit in EBOV-exposed rhesus macaques. Here, we characterize the efficacy of multiple intravenous RDV dosing regimens on survival of rhesus macaques 42 days after intramuscular EBOV exposure.
View Article and Find Full Text PDFCOVID-19 Vaccinations, Infections, and Outcomes Among 784 People Living with HIV.
Viruses
November 2024
Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112102, Israel.
Introduction: Variants of COVID-19 are responsible for 700 million infections and 7 million deaths worldwide. Vaccinations have high efficiency in preventing infection and secondary benefits of reducing COVID-19 hospital admissions, attenuating disease severity and duration of illness. Conflicting reports were published regarding COVID-19 among PLWH.
View Article and Find Full Text PDFMulti-Antigen Elephant Endotheliotropic Herpesvirus (EEHV) mRNA Vaccine Induces Humoral and Cell-Mediated Responses in Mice.
Vaccines (Basel)
December 2024
Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA.
Elephant endotheliotropic herpesvirus (EEHV) causes lethal hemorrhagic disease (HD) in Asian and African elephants in human care and the wild. It is the leading cause of death for young Asian elephants in North American and European zoos despite sensitive diagnostic tests and improved treatments. Thus, there is a critical need to develop an effective vaccine to prevent severe illness and reduce mortality from EEHV-HD.
View Article and Find Full Text PDFThe Dynamics of Antibody Titres Against SARS-CoV-2 in Vaccinated Healthcare Workers: A Systemic Literature Review.
Vaccines (Basel)
December 2024
Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania.
Given that COVID-19 vaccination is a relatively recent development, particularly when compared to immunisation against other diseases, it is crucial to assess its efficacy in vaccinated populations. This literature review analysed studies that monitored antibody titres against SARS-CoV-2 in healthcare workers who received COVID-19 vaccines. Using the PICO (Population, Intervention, Comparators, Outcomes) model recommended in the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines we included 43 publications which analyse antibody dynamics following primary vaccination, the effects of booster doses, and the influence of factors such as COVID-19C infection, age, and sex on antibody kinetics.
View Article and Find Full Text PDFCOVID-19 Vaccine Hesitancy Among Pediatric Oncology and Bone Marrow Transplant Patients.
Vaccines (Basel)
December 2024
Section of Pediatric Oncology and Cellular Therapy, Department of Pediatrics, Alberta Children's Hospital, University of Calgary, Calgary, AB T2N 1N4, Canada.
Vaccine hesitancy among immunocompromised patients is complex and not well understood. This study aimed to determine the rate of COVID-19 vaccine hesitancy among pediatric oncology and bone marrow transplant (BMT) patients and to understand associated factors. : Parents of patients (≤18 years) with cancer or post-BMT completed the Parent Attitudes about Childhood Vaccines Survey.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!